Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80147 |
Name | lymphoblastic lymphoma |
Definition | A lymphoma that has_material_basis_in immature malignant lymphocytes (lymphoblasts) committed to the B-cell or T-cell lineage and located_in primarily lymph nodes or located_in extranodal sites. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma lymphoblastic lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00501826 | Phase II | Nelarabine + Pegaspargase + Venetoclax Cyclophosphamide + Dexamethasone + Doxorubicin + Nelarabine + Pegaspargase + Venetoclax + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisone + Venetoclax + Vincristine Sulfate Cytarabine + Methotrexate + Nelarabine + Pegaspargase + Venetoclax Methotrexate + Pegaspargase + Venetoclax | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Recruiting | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT01658007 | Phase I | Sirolimus | Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma | Terminated | USA | 0 |
NCT02112916 | Phase III | Cyclophosphamide Vincristine Sulfate Ifosfamide Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Leucovorin Daunorubicin Dexamethasone Bortezomib Etoposide Doxorubicin | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma | Active, not recruiting | USA | NZL | CAN | AUS | 0 |
NCT02393157 | Phase II | Carboplatin + Etoposide + Ifosfamide + Obinutuzumab Cytarabine | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE) | Recruiting | USA | 0 |
NCT02793544 | Phase II | Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | Completed | USA | 0 |
NCT02877303 | Phase II | Cyclophosphamide + Dexamethasone + Doxorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Blinatumomab + Inotuzumab ozogamicin Blinatumomab + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Ofatumumab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Vincristine Sulfate | Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT02879643 | Phase I | Dexamethasone + Methotrexate + Pegaspargase + Vincristine sulfate liposome Dexamethasone + Mercaptopurine + Methotrexate + Vincristine sulfate liposome Dexamethasone + Methotrexate + Mitoxantrone + Pegaspargase + Vincristine sulfate liposome | Vincristine Sulfate Liposome Injection (Marqibo) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL | Unknown status | USA | CAN | AUS | 0 |
NCT02906371 | Phase I | Tocilizumab | Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome | Completed | USA | 0 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT03023046 | Phase II | Rituximab Doxorubicin Etoposide Imatinib Dasatinib Cyclophosphamide Prednisone Vincristine Sulfate | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Completed | USA | 0 |
NCT03117751 | Phase II | Cyclophosphamide Vincristine Sulfate Idarubicin Blinatumomab Doxorubicin Clofarabine Vorinostat Ruxolitinib Prednisone Bortezomib Etoposide Dasatinib Daunorubicin Dexamethasone Rituximab Methotrexate Cytarabine Mercaptopurine Pegaspargase | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | Active, not recruiting | USA | AUS | 0 |
NCT03136146 | Phase II | Cyclophosphamide Bortezomib Etoposide Rituximab Ofatumumab Clofarabine Pegfilgrastim | Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) | Recruiting | USA | 0 |
NCT03328104 | Phase I | Cyclophosphamide + Etoposide + Everolimus + Nelarabine | Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma (ENCERT) | Completed | USA | 0 |
NCT03349281 | Phase I | Dexamethasone + Doxorubicin + MLN4924 + Pegaspargase + Vincristine Sulfate | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT03677596 | FDA approved | Inotuzumab ozogamicin | A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients | Completed | USA | TUR | POL | HUN | ESP | 3 |
NCT03792256 | Phase I | Cytarabine + Hydrocortisone + Methotrexate Cytarabine + Doxorubicin + Palbociclib + Pegaspargase + Prednisone + Vincristine Sulfate Methotrexate Cytarabine + Doxorubicin + Palbociclib + Pegaspargase + Prednisolone + Vincristine Sulfate | Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) | Active, not recruiting | USA | 0 |
NCT03914625 | Phase III | Cytarabine + Leucovorin + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Dexamethasone + Methotrexate Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate Blinatumomab + Methotrexate Mercaptopurine + Methotrexate + Vincristine Sulfate Blinatumomab + Dexamethasone + Leucovorin + Methotrexate Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Leucovorin + Methotrexate Blinatumomab + Dexamethasone + Leucovorin Mercaptopurine + Methotrexate + Prednisolone + Vincristine Sulfate Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Leucovorin + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Leucovorin + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Leucovorin + Methotrexate + Vincristine Sulfate Methotrexate + Vincristine Sulfate Dexamethasone + Mercaptopurine + Methotrexate + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Cytarabine + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Dexamethasone + Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate | Blinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic Lymphoma | Active, not recruiting | USA | NZL | CAN | AUS | 1 |
NCT03962465 | Phase I | Daunorubicin + Inotuzumab ozogamicin + Pegaspargase + Prednisone + Vincristine Sulfate Daunorubicin + Inotuzumab ozogamicin + Prednisone + Vincristine Sulfate Cytarabine Methotrexate | Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (ALL-001) | Active, not recruiting | USA | 0 |
NCT04145531 | Phase II | JZP-458 | An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | Completed | USA | CAN | 0 |
NCT04334993 | Phase II | Blinatumomab | Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study | Recruiting | ISR | 0 |
NCT04984356 | Phase Ib/II | WU-CART-007 | A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL | Completed | USA | NLD | FRA | AUS | 0 |
NCT05032183 | Phase Ib/II | Cytarabine + Filgrastim + Methotrexate + Rituximab + Tagraxofusp-erzs Cyclophosphamide + Dexamethasone + Mesna + Methotrexate + Rituximab + Tagraxofusp-erzs + Vincristine Sulfate Tagraxofusp-erzs | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Active, not recruiting | USA | 0 |
NCT05038644 | Phase I | XmAb18968 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT05054465 | Phase Ib/II | Navitoclax + Venetoclax | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL (ITALLI001) | Not yet recruiting | ISR | 0 |
NCT05292664 | Phase I | Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax | Venetoclax Basket Trial for High Risk Hematologic Malignancies | Recruiting | USA | 0 |
NCT05303792 | Phase II | Cytarabine + Methotrexate + Methylprednisolone Cyclophosphamide + Dexamethasone + Mesna + Vincristine Sulfate Cytarabine + Inotuzumab ozogamicin + Methotrexate + Methylprednisolone Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Mesna + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Mesna + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Mesna + Rituximab + Vincristine Sulfate Cytarabine + Methotrexate + Methylprednisolone + Rituximab Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cytarabine + Inotuzumab ozogamicin + Methotrexate + Methylprednisolone + Rituximab | Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma | Recruiting | USA | 1 |
NCT05418088 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19/CD20/CD22 CAR-T Cells | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05442515 | Phase Ib/II | CD19/CD22 CAR T cells Cyclophosphamide + Fludarabine | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Recruiting | USA | 0 |
NCT05464836 | Phase II | CB-103 + Venetoclax | Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL | Terminated | USA | 0 |
NCT05480449 | Phase Ib/II | huCART19 | Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) | Recruiting | USA | 0 |
NCT05658640 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dexamethasone + Trametinib | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D) | Recruiting | SWE | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CHE | BEL | AUT | 0 |
NCT05740449 | Phase Ib/II | Decitabine + Navitoclax + Venetoclax | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A) | Withdrawn | NLD | 0 |
NCT05745714 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dexamethasone + Ruxolitinib + Venetoclax | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C) | Not yet recruiting | NLD | 0 |
NCT05751044 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Venetoclax | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B) | Not yet recruiting | NLD | 0 |
NCT06064903 | Phase Ib/II | Cyclophosphamide + Fludarabine CD7-CART01 cells | CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL (CD7-CAR01) | Recruiting | ITA | 0 |
NCT06207123 | Phase Ib/II | Dexamethasone + Methotrexate + Vincristine Sulfate LP-118 + Ponatinib | A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) | Recruiting | USA | 0 |
NCT06533748 | Phase II | Blinatumomab + Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Inotuzumab ozogamicin + Methotrexate + Vincristine Sulfate Blinatumomab + Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Inotuzumab ozogamicin + Mercaptopurine + Methotrexate + Vincristine Sulfate Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Thioguanine + Vincristine Sulfate | Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma | Not yet recruiting | USA | 0 |
NCT06561074 | Phase II | Calaspargase pegol-mknl + Decitabine + Venetoclax | A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) | Not yet recruiting | USA | 0 |